Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Karim Fizazi, Arun A Azad, Nobuaki Matsubara, Joan Carles, André P Fay, Ugo De Giorgi, Jae Young Joung, Peter C C Fong, Eric Voog, Robert J Jones, Neal D Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Matko Kalac, A Douglas Laird, Dana Kennedy, Neeraj Agarwal

Open source

DOI: 10.1016/s0140-6736(25)00683-x
Published: 2025-08
Container: The Lancet
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-00683-x,
  title = {Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial},
  author = {Karim Fizazi and Arun A Azad and Nobuaki Matsubara and Joan Carles and André P Fay and Ugo De Giorgi and Jae Young Joung and Peter C C Fong and Eric Voog and Robert J Jones and Neal D Shore and Curtis Dunshee and Stefanie Zschäbitz and Jan Oldenburg and Dingwei Ye and Xun Lin and Matko Kalac and A Douglas Laird and Dana Kennedy and Neeraj Agarwal},
  year = {2025},
  journal = {The Lancet},
  doi = {10.1016/s0140-6736(25)00683-x},
  url = {https://doi.org/10.1016/s0140-6736(25)00683-x}
}

RIS

TY  - JOUR
TI  - Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
AU  - Karim Fizazi
AU  - Arun A Azad
AU  - Nobuaki Matsubara
AU  - Joan Carles
AU  - André P Fay
AU  - Ugo De Giorgi
AU  - Jae Young Joung
AU  - Peter C C Fong
AU  - Eric Voog
AU  - Robert J Jones
AU  - Neal D Shore
AU  - Curtis Dunshee
AU  - Stefanie Zschäbitz
AU  - Jan Oldenburg
AU  - Dingwei Ye
AU  - Xun Lin
AU  - Matko Kalac
AU  - A Douglas Laird
AU  - Dana Kennedy
AU  - Neeraj Agarwal
PY  - 2025
JO  - The Lancet
DO  - 10.1016/s0140-6736(25)00683-x
UR  - https://doi.org/10.1016/s0140-6736(25)00683-x
ER  -

APA

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Kalac, M., Laird, A. D., Kennedy, D., & Agarwal, N. (2025). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)00683-x

Source records

crossref · retrieved 2026-09-27T04:07:08.852Z